Compare Endeavour Silver Corp (EXK) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Eli Lilly And Co — how do they compare? Endeavour Silver Corp trades at $7.55 (market cap $2.36B), while Eli Lilly And Co trades at $1,185.96 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 436.4× Endeavour Silver Corp's market cap, and Eli Lilly And Co pays a 0.6% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals.
| EXK | LLY | |
|---|---|---|
Market Cap | $2.36B | $1.03T |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $1.24K |
52-Week Low | $4.96 | $625.65 |
Enterprise Value | $2.36B | $1.07T |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $7.625, down 5.63% today, with a bearish technical signal from moving averages. The company reported a Q1 2026 earnings beat of $0.21 per share versus $0.10 expected, driven by record production. However, 2025 financials show a net loss of $119.1 million despite revenue growth, with negative profit margins and ROE. Analyst consensus is strongly bullish with 11 buy ratings.
Outlook hinges on operational execution and silver price trends. Investment opportunity exists from production growth and potential margin improvement, but risks include sustained negative profitability, high debt-to-asset ratio, and commodity price volatility. Cash flow trends show improvement into 2026, supporting near-term stability.
LLY trades at $1,154.27, down 2.6% today, amid a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $8.55 surpassing the $6.97 forecast. Revenue surged to $65.18B in 2025, driving a net income margin of 34.99%. Recent news includes the acquisition of AtaiBeckley for $2.8 billion, expanding its neuroscience pipeline.
Outlook remains positive with a consensus price target of $1,380, though high valuation multiples (P/E 41.09) and competitive pressures in obesity drugs present risks. Analyst sentiment is strongly bullish (73% buy ratings), supporting further upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
